HONG KONG, July 22 /PRNewswire-Asia-FirstCall/ —
China’s leading integrated medical enterprise Golden Meditech
Holdings Limited (“Golden Meditech” or the “Group,” HKEx: 801) is
pleased to announce its annual results for the year ended 31 March 2010. During the reporting period,
total turnover amounted to HK$285,467,000 (the Group ceased to
consolidate revenue from the cord blood banking division into its
financial statements), representing a y-o-y increase of 3.2%; the
Group’s profit from continuing operations amounted to HK$134,395,000, tripled that from the
previous year.
To maintain the liquidity of the Company’s shares, the Company
has issued convertible notes and warrants during the reporting
period with a principal amount of US$25,200,000 and US$8,400,000 respectively which are due in
2014. As the Company’s shares price has increased after the
issuances, a non-cash expense of HK$102,357,000 has been recognised,
impacting the Group’s profit attributable to equity holders, which
has increased by 104% at HK$116,412,000 while basic earnings per
share amounted to HK 7.2 cents.
Excluding the said expense, profit attributable to equity
shareholders would be HK$218,769,000,
representing a y-o-y increase of 283%, while earnings per share
would be HK13.7 cents. As of the date of announcement, 52% of the
convertible notes have been converted into ordinary shares of the
Company. The Company does not declare a dividend during the
reporting period, though it does not rule out the possibility of
sharing with our valuable shareholders benefits from the public
offerings in the f
‘/>”/>
